RESUMEN
We aim to assess the relationship between validated smoking cessation pharmacotherapies and electronic cigarettes (e-cigarettes) and insomnia and parasomnia using a systematic review and a network meta-analysis. A systematic search was performed until August 2022 in the following databases: PUBMED, COCHRANE, CLINICALTRIAL. Randomized controlled studies against placebo or validated therapeutic smoking cessation methods and e-cigarettes in adult smokers without unstable or psychiatric comorbidity were included. The primary outcome was the presence of "insomnia" and "parasomnia." A total of 1261 studies were selected. Thirty-seven studies were included in the quantitative analysis (34 for insomnia and 23 for parasomnia). The reported interventions were varenicline (23 studies), nicotine replacement therapy (NRT, 10 studies), bupropion (15 studies). No studies on e-cigarettes were included. Bayesian analyses found that insomnia and parasomnia are more frequent with smoking cessation therapies than placebo except for bupropion. Insomnia was less frequent with nicotine substitutes but more frequent with bupropion than the over pharmacotherapies. Parasomnia are less frequent with bupropion but more frequent with varenicline than the over pharmacotherapies. Validated smoking cessation pharmacotherapies can induce sleep disturbances with different degrees of frequency. Our network meta-analysis shows a more favorable profile of nicotine substitutes for insomnia and bupropion for parasomnia. It seems essential to systematize the assessment of sleep disturbances in the initiation of smoking cessation treatment. This could help professionals to personalize the choice of treatment according to sleep parameters of each patient. Considering co-addictions, broadening the populations studied and standardizing the measurement are additional avenues for future research.
Asunto(s)
Sistemas Electrónicos de Liberación de Nicotina , Metaanálisis en Red , Parasomnias , Trastornos del Inicio y del Mantenimiento del Sueño , Cese del Hábito de Fumar , Humanos , Cese del Hábito de Fumar/métodos , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Parasomnias/inducido químicamente , Agentes para el Cese del Hábito de Fumar/uso terapéutico , Agentes para el Cese del Hábito de Fumar/efectos adversos , Dispositivos para Dejar de Fumar Tabaco , Vareniclina/uso terapéutico , Vareniclina/efectos adversos , Bupropión/uso terapéutico , Bupropión/efectos adversosRESUMEN
BACKGROUND: Sleep walking (SW) is a parasomnia behavior characterized by repetitious occurrence of ambulation during a partial arousal from non-rapid eye movement (NREM) sleep. Sleep-related eating (SRE) is one of the complex sleep behaviors that may accompany SW. Emerging evidence suggests that NREM parasomnias can be associated with atypical antipsychotic medication use. METHODS: We present a case series (nâ¯=â¯5) and a systematic review of the literature of cases of SW, with or without SRE (nâ¯=â¯23), associated with atypical antipsychotic use. RESULTS: Twenty-eight cases of SW, with and without SRE, with a mean age of 44.8â¯years (S.D. = 15.04) and a male predominance (75%; nâ¯=â¯21) were identified. Quetiapine was the most commonly implicated medication with SW and SRE (nâ¯=â¯14). Remission from SW/SRE was noted in all cases with measures including antipsychotic dosage reduction, discontinuation of medication, switching to an alternate medication, and use of continuous positive airway pressure (CPAP) for comorbid obstructive sleep apnea (OSA) treatment. CONCLUSIONS: Sleep walking (SW), with or without sleep related eating (SRE), can be a rare but reversible side effect associated with use of atypical antipsychotics. More research is warranted to elucidate the mechanisms underlying SW and SRE associated with atypical antipsychotic use.
Asunto(s)
Antipsicóticos/efectos adversos , Conducta Alimentaria/efectos de los fármacos , Parasomnias/inducido químicamente , Fumarato de Quetiapina/efectos adversos , Sonambulismo/inducido químicamente , Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
PURPOSE: To identify and analyze postmarketing cases of complex sleep behaviors (CSBs) resulting in serious injuries, including death, associated with eszopiclone, zaleplon, or zolpidem (Z-drugs). METHODS: Retrospective analysis of the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from 16 December 1992 through 27 February 2018 and medical literature using PubMed and EMBASE. We used random sampling and descriptive statistics. RESULTS: We identified 66 cases that met inclusion and exclusion criteria, four of which were identified in the medical literature. Twenty cases reported death and 46 cases reported serious injuries in association with CSBs occurring after the use of a Z-drug. Fatal cases described events, such as carbon monoxide poisoning, drowning, falls, hypothermia, motor vehicle collisions, and apparent completed suicide. Nonfatal cases resulting in serious injuries described events, such as accidental overdoses, falls, gunshot wounds, hypothermia, third-degree burns, and self-injuries or suicide attempts. Twenty-two cases reported a previous episode of a CSB while taking a Z-drug prior to the event reported in this case series. CONCLUSIONS: The FAERS and medical literature cases support the need for increased awareness of the consequences that may occur because of CSBs associated with the use of Z-drugs. Therefore, to protect public health, regulatory actions were taken, including adding a Boxed Warning, a Contraindication in patients who have experienced a prior episode of a CSB with a Z-drug, and updating the existing Warnings and Precautions. An FDA Drug Safety Communication was also disseminated to alert healthcare professionals and the public of this potential risk.
Asunto(s)
Acetamidas/efectos adversos , Eszopiclona/efectos adversos , Parasomnias/inducido químicamente , Pirimidinas/efectos adversos , Fármacos Inductores del Sueño/efectos adversos , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Sueño/efectos de los fármacos , Heridas y Lesiones/inducido químicamente , Zolpidem/efectos adversos , Adulto , Sistemas de Registro de Reacción Adversa a Medicamentos , Anciano , Etiquetado de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Parasomnias/mortalidad , Parasomnias/fisiopatología , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Trastornos del Inicio y del Mantenimiento del Sueño/diagnóstico , Trastornos del Inicio y del Mantenimiento del Sueño/fisiopatología , Sonambulismo/inducido químicamente , Sonambulismo/mortalidad , Sonambulismo/fisiopatología , Factores de Tiempo , Resultado del Tratamiento , Heridas y Lesiones/mortalidad , Heridas y Lesiones/fisiopatologíaRESUMEN
Sleep-related eating disorder (SRED) is characterized by recurrent episodes of eating during the night, accompanied by partial consciousness and followed by limited recall. Zolpidem is a sedative-hypnotic drug commonly used to treat sleep disorders. Zolpidem reduces sleep latency and increases the total time of sleep. Here, we described a case of a patient with attention-deficit/hyperactivity disorder (ADHD) who suffered from zolpidem-induced SRED. The symptoms disappeared when the use of zolpidem as discontinuation. To the best of our knowledge, this is the first documented case of SRED induced by the use of zolpidem in a patient with ADHD.
Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad , Trastornos de Alimentación y de la Ingestión de Alimentos/inducido químicamente , Parasomnias/inducido químicamente , Fármacos Inductores del Sueño/efectos adversos , Zolpidem/efectos adversos , Adulto , Femenino , Humanos , Adulto JovenAsunto(s)
Agonistas de Dopamina/efectos adversos , Parasomnias/inducido químicamente , Polisomnografía/métodos , Pramipexol/efectos adversos , Nivel de Alerta/efectos de los fármacos , Agonistas de Dopamina/uso terapéutico , Femenino , Humanos , Persona de Mediana Edad , Parasomnias/diagnóstico , Pramipexol/uso terapéutico , Síndrome de las Piernas Inquietas/tratamiento farmacológico , Trastornos del Despertar del Sueño/inducido químicamenteRESUMEN
ABSTRACT: The most common sleep disorders that can result in injurious or violent behaviors include REM sleep behavioral disorder, sleepwalking, comorbid parasomnias, sleep-related dissociative disorder, and obstructive sleep apnea. Video polysomnography is usually indicated to evaluate recurring sleep-related injury in adults. Only one-third of patients with complex paroxysmal nocturnal events will have one of their habitual events on a single night of in-laboratory video polysomnography, most often those who have prominent, high-frequency motor features. We report evidence of sleep walking induced by sodium oxybate identified by steps recorded on a consumer wearable device coinciding with clinical history and evidence of injury.
Asunto(s)
Polisomnografía , Oxibato de Sodio/efectos adversos , Sonambulismo/inducido químicamente , Grabación en Video , Adulto , Trastornos de Somnolencia Excesiva/diagnóstico , Diseño de Equipo , Femenino , Humanos , Narcolepsia/diagnóstico , Parasomnias/inducido químicamente , Parasomnias/diagnóstico , Polisomnografía/instrumentación , Oxibato de Sodio/uso terapéutico , Sonambulismo/diagnósticoRESUMEN
Sleep-related eating disorder (SRED) is classified within parasomnia and is characterised by recurrent episodes of abnormal, dysfunctional eating during sleep. This report describes a case of SRED in a 19-year-old woman admitted to the psychiatric ward with worsening anxiety, low mood and suicidal ideation. She was started on low-dose mirtazapine for mood stabilisation and, following an incremental increase to 30 mg, she developed nocturnal binge eating of which she retained only partial memory on waking. She developed adverse health consequences as a result of these recurrent episodes. The subject's symptoms were relieved rapidly following reduction of the dose of mirtazapine back to 15 mg.
Asunto(s)
Antidepresivos/efectos adversos , Trastorno Depresivo/tratamiento farmacológico , Trastornos de Alimentación y de la Ingestión de Alimentos/diagnóstico , Mirtazapina/efectos adversos , Parasomnias/diagnóstico , Diagnóstico Diferencial , Trastornos de Alimentación y de la Ingestión de Alimentos/inducido químicamente , Femenino , Humanos , Parasomnias/inducido químicamente , Adulto JovenRESUMEN
ABSTRACT: Suvorexant is a new insomnia drug, and it is generally safe and well tolerated. Here, we report a rare but potentially important adverse effect of suvorexant in a patient with Parkinson disease.
Asunto(s)
Azepinas/efectos adversos , Parasomnias/inducido químicamente , Enfermedad de Parkinson/complicaciones , Fármacos Inductores del Sueño/efectos adversos , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Triazoles/efectos adversos , Anciano , Azepinas/uso terapéutico , Sueños/efectos de los fármacos , Humanos , Masculino , Parasomnias/complicaciones , Fármacos Inductores del Sueño/uso terapéutico , Triazoles/uso terapéuticoAsunto(s)
Antipsicóticos/efectos adversos , Trastornos de Alimentación y de la Ingestión de Alimentos/inducido químicamente , Parasomnias/inducido químicamente , Piperazinas/efectos adversos , Trastornos Psicóticos/tratamiento farmacológico , Tiazoles/efectos adversos , Adulto , Humanos , Masculino , Sonambulismo/inducido químicamenteAsunto(s)
Adyuvantes Anestésicos/efectos adversos , Trastornos de Alimentación y de la Ingestión de Alimentos/inducido químicamente , Parasomnias/inducido químicamente , Oxibato de Sodio/efectos adversos , Adyuvantes Anestésicos/uso terapéutico , Adulto , Femenino , Humanos , Narcolepsia/tratamiento farmacológico , Oxibato de Sodio/uso terapéuticoRESUMEN
Sleep dysfunction is a pervasive issue in schizophrenia and psychosis. Current knowledge is drawn almost exclusively from studies using quantitative research methodologies that include measures and tools developed in healthy population groups. Qualitative studies investigating the first-person perspectives of sleep problems are therefore important for designing better assessment and treatment tools to meet consumer needs. Focus groups were conducted to elicit detailed information regarding the personal experience of sleep problems, their antecedents and impact, in 14 individuals with schizophrenia-spectrum disorder who experienced insomnia during their illness. Thematic analysis was applied to examine the data and draw treatment implications for sleep management. Insomnia was ubiquitous and frequently co-occurred with other sleep difficulties (nightmares, sleep walking, acting out dreams, etc.) in this group. Discussions revealed themes common across insomnia populations (role of negative mood states and cognitive intrusions) and also new themes on factors contributing to sleep problems in schizophrenia: (1) beliefs that sleep problems cannot be changed; (2) trauma and adversity; (3) lifestyle choices and lack of motivation; and (4) medication side effects. Sleep problems also had profound impact on daytime dysfunctions and disability. The findings point to novel issues that may benefit from consideration in the treatment of sleep problems in schizophrenia. Unhelpful cognitions and behaviours about sleep can be addressed with psychological interventions, activity scheduling and motivational interviewing techniques. Seeking a first-person perspective is vital for identifying issues that will impact on treatment success and recovery.
Asunto(s)
Actitud Frente a la Salud , Parasomnias/psicología , Esquizofrenia/terapia , Psicología del Esquizofrénico , Trastornos del Inicio y del Mantenimiento del Sueño/psicología , Adulto , Antipsicóticos/efectos adversos , Cognición , Terapia Cognitivo-Conductual , Comorbilidad , Femenino , Grupos Focales , Humanos , Estilo de Vida , Masculino , Motivación , Parasomnias/inducido químicamente , Parasomnias/terapia , Trastornos Psicóticos/psicología , Trastornos Psicóticos/terapia , Investigación Cualitativa , Trastornos del Inicio y del Mantenimiento del Sueño/inducido químicamente , Trastornos del Inicio y del Mantenimiento del Sueño/terapia , Trastornos del Sueño-Vigilia/inducido químicamente , Trastornos del Sueño-Vigilia/psicología , Trastornos del Sueño-Vigilia/terapiaRESUMEN
STUDY OBJECTIVES: To assess adverse drug reaction reports of "abnormal sleep related events" associated with varenicline, a partial agonist to the α4ß2 subtype of nicotinic acetylcholine receptors on neurones, indicated for smoking cessation. DESIGN: Twenty-seven reports of "abnormal sleep related events" often associated with abnormal dreams, nightmares, or somnambulism, which are known to be associated with varenicline use, were identified in the World Health Organisation (WHO) Global Individual Case Safety Reports Database. Original anonymous reports were obtained from the four national pharmacovigilance centers that submitted these reports and assessed for reaction description and causality. MEASUREMENTS AND RESULTS: These 27 reports include 10 of aggressive activity occurring during sleep and seven of other sleep related harmful or potentially harmful activities, such as apparently deliberate self-harm, moving a child or a car, or lighting a stove or a cigarette. Assessment of these 17 reports of aggression or other actual or potential harm showed that nine patients recovered or were recovering on varenicline withdrawal and there were no consistent alternative explanations. Thirteen patients experienced single events, and two had multiple events. Frequency was not stated for the remaining two patients. CONCLUSIONS: The descriptions of the reports of aggression during sleep with violent dreaming are similar to those of rapid eye movement sleep behavior disorder and also nonrapid eye movement (NREM) sleep parasomnias in some adults. Patients who experience somnambulism or dreams of a violent nature while taking varenicline should be advised to consult their health providers. Consideration should be given to clarifying the term sleep disorders in varenicline product information and including sleep related harmful and potentially harmful events.
Asunto(s)
Agresión/efectos de los fármacos , Benzazepinas/efectos adversos , Sueños/efectos de los fármacos , Agonistas Nicotínicos/efectos adversos , Quinoxalinas/efectos adversos , Trastornos del Sueño-Vigilia/inducido químicamente , Adulto , Etiquetado de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Parasomnias/inducido químicamente , Farmacovigilancia , Cese del Hábito de Fumar/psicología , Sonambulismo/inducido químicamente , Vareniclina , Organización Mundial de la SaludRESUMEN
Sleep-related eating disorder (SRED) is a condition characterized by recurrent episodes of eating at the transition from night-time sleep to arousal. SRED patients describe eating in an out-of-control manner with preference for high-caloric foods and sometimes with inedible or toxic items. Level of consciousness during SRED episodes ranges from partial consciousness to dense unawareness typical of somnambulistic episodes. SRED is sometimes associated with psychotropic medication, in particular sedative hypnotics, and other sleep disorders, including parasomnias, narcolepsy, and restless legs syndrome. Night eating syndrome (NES) is another important condition in the disordered night-time eating spectrum showing hyperphagia episodes at full arousal from nocturnal sleep without accompanying amnesia. NES could be considered an abnormality in the circadian rhythm of meal timing with a normal circadian timing of sleep onset. The two conditions often overlap and possibly share a common pathophysiology. Studies have suggested that central nervous system serotonin modulation may lead to an effective treatment of NES, while the anti-seizure medication topiramate may be an effective SRED treatment.
Asunto(s)
Trastornos de Alimentación y de la Ingestión de Alimentos/epidemiología , Hiperfagia/epidemiología , Trastornos Mentales/epidemiología , Narcolepsia/epidemiología , Parasomnias/epidemiología , Síndrome de las Piernas Inquietas/epidemiología , Comorbilidad , Trastornos de Alimentación y de la Ingestión de Alimentos/inducido químicamente , Trastornos de Alimentación y de la Ingestión de Alimentos/diagnóstico , Trastornos de Alimentación y de la Ingestión de Alimentos/fisiopatología , Humanos , Hiperfagia/inducido químicamente , Hiperfagia/diagnóstico , Hiperfagia/fisiopatología , Hipnóticos y Sedantes/efectos adversos , Parasomnias/inducido químicamente , Parasomnias/diagnóstico , Parasomnias/fisiopatologíaRESUMEN
OBJECTIVE: Complex sleep-related behaviors (CSBs) are often associated with hypnotic use, especially zolpidem. The age effect on the occurrence of CSBs has not been adequately investigated. This study aimed to investigate and compare the clinical correlates of CSBs between adult and elderly subjects who were taking zolpidem. METHOD: A total of 253 adults (aged 20-55 years) and 64 elderly subjects (aged ≥ 65 years) who were administered zolpidem for at least 3 months were enrolled from psychiatric outpatient clinics from June 2011 to May 2012. The sociodemographic characteristics of the participants, the dose of zolpidem, and the occurrence of CSBs were collected. Logistic regression analysis was used to examine the clinical correlates of CSBs. RESULTS: In total, there were 62 members of the adult group (24.5%) and 11 elderly subjects (17.2%) with CSBs; however, the difference did not reach statistical significance. Logistic regression analysis showed that there was a main effect of zolpidem dose (≥ 10 mg; OR = 2.82, P = .038) and alcohol use (OR = 2.05, P = .026), but not sex or age group. There were interactive effects between age group and zolpidem dose (P = .043), indicating that a higher dose of zolpidem was associated with CSBs only in the adult group and not in the elderly group. Adults with CSBs used a higher dose of zolpidem than adults without (mean ± SD: 15.4 ± 6.8 mg vs 11.3 ± 5.7 mg), whereas elderly patients with CSBs did not use a higher dose of zolpidem than those without (12.2 ± 5.4 mg vs 11.9 ± 7.0 mg). CONCLUSIONS: A higher dose of zolpidem was correlated with CSBs only in the adult group and not in the elderly group. Future studies investigating the factors, other than dose, related to CSBs in the elderly will be performed.
Asunto(s)
Hipnóticos y Sedantes/efectos adversos , Parasomnias/inducido químicamente , Piridinas/efectos adversos , Adulto , Factores de Edad , Anciano , Consumo de Bebidas Alcohólicas/efectos adversos , Femenino , Humanos , Hipnóticos y Sedantes/administración & dosificación , Masculino , Persona de Mediana Edad , Piridinas/administración & dosificación , Adulto Joven , ZolpidemRESUMEN
Zolpidem is associated with an amnestic sleep-related eating disorder, but not with compulsive eating behaviors. A 57-year-old woman receiving zolpidem for insomnia showed compulsive evening eating behavior under a wakeful state. Her compulsive evening eating behavior disappeared when zolpidem treatment was halted. Here, we report her case.
Asunto(s)
Conducta Compulsiva/inducido químicamente , Trastornos de Alimentación y de la Ingestión de Alimentos/inducido químicamente , Hipnóticos y Sedantes/efectos adversos , Parasomnias/inducido químicamente , Piridinas/efectos adversos , Femenino , Humanos , Persona de Mediana Edad , ZolpidemRESUMEN
PURPOSE: This study aims to report on catathrenia occurring in narcolepsy with cataplexy (NC) patients under sodium oxybate (SO) treatment. Catathrenia is a parasomnia characterized by groaning and an abnormal respiratory pattern during sleep. METHODS: Fifty-one patients with NC and starting SO therapy underwent a baseline overnight polysomnography (PSG) to detect any sleep-related breathing disorders (SRBD). To avoid risks due to a possible central respiratory control depression by SO, all patients with concomitant obstructive sleep apnea (OSA) were treated with a nasal continuous positive airway pressure (nCPAP) device. After 2 months of treatment with SO, all patients underwent a follow-up overnight PSG to investigate possible newly occurring SRBD. They also underwent a semi-structured clinical interview to monitor other potential SO side effects. RESULTS: At baseline, four out of 51 patients showed simple snoring, and eight, mild to severe OSA. After a titration PSG night, patients with OSA received a nCPAP device. After 2 months of SO treatment, 28 patients (54.9%) showed SO-related side effects, including SRBD in 11 (21.6%). The follow-up PSG showed a respiratory pattern characteristic of catathrenia in seven patients (13.7%) as a newly observed and possibly benign SO side effect, and ruled out a worsening of OSA. CONCLUSIONS: Catathrenia should be considered a possible side effect in NC patients under SO treatment and should be accurately identified to prevent unnecessary SO withdrawal.
Asunto(s)
Cataplejía/tratamiento farmacológico , Depresores del Sistema Nervioso Central/efectos adversos , Narcolepsia/tratamiento farmacológico , Parasomnias/inducido químicamente , Oxibato de Sodio/efectos adversos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Depresores del Sistema Nervioso Central/uso terapéutico , Niño , Terapia Combinada , Comorbilidad , Presión de las Vías Aéreas Positiva Contínua , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Polisomnografía/efectos de los fármacos , Apnea Obstructiva del Sueño/tratamiento farmacológico , Oxibato de Sodio/uso terapéutico , Adulto JovenRESUMEN
Hypnosedative-induced complex behaviors have gained increased attention in recent years as a potential complication of benzodiazepines and benzodiazepine-receptor agonist use. Sodium oxybate (SO), the sodium salt of γ-hydroxybutyrate, an inhibitory neurotransmitter, has been associated with dose-dependent rates of somnambulism; however, there is limited information about complex motor behaviors with SO. We describe a patient with narcolepsy-cataplexy who experienced one episode of sleep-driving and at least two sleep-related eating episodes with therapeutic doses of SO.